Welcome to our dedicated page for Exelixis SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exelixis, Inc. (EXEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed oncology-focused biopharmaceutical company, Exelixis uses these filings to report material events, financial results, capital allocation decisions and changes in senior leadership.
Form 8-K filings for EXEL include items such as quarterly financial results and corporate updates, stock repurchase program authorizations and executive appointments or departures. For example, Exelixis has filed 8-Ks describing the authorization of a stock repurchase program for up to a specified amount of common stock before a stated date, as well as the appointment of an Executive Vice President, Research and Development and the planned transition of its General Counsel role. These filings complement the company’s earnings press releases by providing structured information on results of operations and significant corporate actions.
Investors and analysts can use Exelixis’ SEC filings to track how the company reports revenue from its cabozantinib franchise, outlines research and development and selling, general and administrative expenses, and communicates guidance ranges for future periods. While detailed financial statements and management discussion are found in periodic reports such as Forms 10-K and 10-Q, current reports on Form 8-K highlight timely developments that may affect the company’s outlook or governance.
On Stock Titan, EXEL filings are accompanied by AI-powered summaries designed to clarify the key points in complex documents. These summaries help readers quickly understand the implications of new filings, from capital return plans to leadership changes, while links to the full text allow for deeper review. The filings page also serves as a starting point for researching topics such as repurchase authorizations, executive transitions and other events that Exelixis has deemed material enough to disclose under SEC rules.
Aftab Dana reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. executive vice president of research and development Dana Aftab reported an equity compensation grant in the form of restricted stock units (RSUs). The award covers 52,018 shares of common stock, granted under the company’s 2017 Equity Incentive Plan at no cash cost.
These RSUs will vest as to one quarter of the original grant on May 15, 2027, and one quarter on each following May 15 until fully vested. Following this grant, Aftab’s directly held common stock position, including previously granted RSUs and performance-based RSUs, totals 668,124 shares, of which 466,061 shares relate to unvested RSUs and a prior performance-based award. In addition, 5,835 shares are held indirectly through the Exelixis 401(k) Plan as of a statement dated February 26, 2026.
EXELIXIS, INC. Executive Vice President and CFO Christopher J. Senner reported an equity compensation award in the form of restricted stock units tied to the company’s common stock. The filing shows an acquisition of 52,018 shares of common stock at a price of $0.00 per share, representing RSUs granted under the Exelixis, Inc. 2017 Equity Incentive Plan that will be issued upon vesting. These RSUs vest in four equal annual installments, beginning May 15, 2027 and then each May 15 thereafter until fully vested. After this grant, Senner directly owns or has rights to 1,028,110 shares of common stock, including 479,708 shares that will be issued upon vesting of previously granted RSUs and performance-based restricted stock units. He also indirectly holds 2,723 shares through the Exelixis, Inc. 401(k) Plan as of February 26, 2026.
Hefti Brenda reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. senior vice president and general counsel Brenda Hefti received an equity award in the form of restricted stock units (RSUs) tied to the company’s common stock. The grant covers 23,119 shares that will be issued as the RSUs vest over time.
According to the grant terms, one-quarter of the original RSU amount will vest on May 15, 2027, with additional one-quarter installments vesting on each May 15 thereafter until fully vested. Following this award, Hefti has 119,631 shares of common stock reported as directly owned, including shares underlying previously granted RSUs and performance-based restricted stock units, and 5,527 shares held indirectly through the company’s 401(k) plan.
Haley Patrick J. reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. executive Patrick J. Haley, EVP, Commercial, received an equity grant of 40,459 restricted stock units (RSUs) of common stock. The RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan and carry no purchase price.
The award will vest as to one-quarter of the original RSU share amount on May 15, 2027, and one-quarter on each May 15 thereafter until fully vested. Following this grant, a total of 422,367 shares of common stock are scheduled to be issued to Haley upon vesting of RSUs and a performance-based restricted stock unit award granted on March 31, 2025.
EXELIXIS, INC. President and CEO Michael Morrissey reported both an equity award and a charitable gift of company stock. On February 26, 2026, he was granted 160,437 restricted stock units (RSUs) under the Exelixis, Inc. 2017 Equity Incentive Plan at no cash cost.
The RSUs will vest as to one-quarter of the original shares on May 15, 2027 and then one-quarter on each May 15 thereafter until fully vested. Following this grant, 1,614,552 shares of common stock are scheduled to be issued to him upon vesting of RSUs and a performance-based restricted stock unit award granted on March 31, 2025.
Separately, on February 24, 2026, shares held by the Morrissey Family Living Trust were used to make a bona fide gift of 100,278 shares of Exelixis common stock to the Bombora Rise Foundation. In addition, 17,728 shares are held for his benefit under the Exelixis, Inc. 401(k) Plan as of February 26, 2026.
Exelixis EVP of Research and Development Dana Aftab reported an open-market sale of 47,918 shares of common stock at $44.50 per share. After this sale, Aftab directly holds 616,106 shares, which include 414,043 shares tied to unvested RSUs and PSUs.
Aftab also indirectly holds 5,835 shares through the Exelixis 401(k) plan, based on a statement dated February 23, 2026.
EXEL reported an insider sale. Dana T Aftab sold 29,873 common shares on 02/19/2026 for $1,324,867.55. The filing also lists prior issuances of performance shares and restricted stock with dated grants: 20,006 (01/11/2024), 6,385 (08/15/2023), 8,757 (05/15/2023), and 12,770 (09/06/2023).
EXELIXIS, INC. executive vice president of research and development Dana Aftab reported an open-market sale of 29,873 shares of common stock on February 19, 2026 at a price of $44.35 per share. After this sale, Aftab directly holds 664,024 shares of Exelixis common stock.
In addition, Aftab has an indirect holding of 5,835 shares through the Exelixis 401(k) Plan based on a statement dated February 18, 2026. Footnotes also state that 414,043 shares are scheduled to be issued upon vesting of previously granted RSUs and performance stock units.
Exelixis, Inc. director Jack L. Wyszomierski reported option exercises and share sales. On February 18, 2026, he exercised an option for 20,634 shares of common stock, converting an "Option (right to buy)" that had become fully exercisable on May 23, 2019.
On the same date, he sold 99,574 shares of Exelixis common stock at a weighted average price of $44.01 per share, in multiple trades ranging from $43.32 to $44.49, under a pre-established Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 279,942 shares of common stock, including 9,812 shares that will be issued upon vesting of restricted stock units.
EXELIXIS, INC. director Julie Smith reported combined option exercises and stock sales. On February 17–18, 2026, she exercised options covering a total of 106,539 shares of common stock at exercise prices of $18.19, $19.39 and $21.69 per share.
Over the same two days she sold 106,539 shares of Exelixis common stock in open-market transactions at prices including $43.33, $44.30 and $44.50 per share, resulting in a net sale position. After these trades she directly owned 20,590 shares of common stock, and a footnote states she also holds 9,812 restricted stock units that will settle into common shares upon vesting.